Medical Data Vision Co., Ltd.
Medical Data Vision Co., Ltd. Fundamental Analysis
Medical Data Vision Co., Ltd. (3902.T) shows weak financial fundamentals with a PE ratio of 227.48, profit margin of 4.29%, and ROE of 9.63%. The company generates $6.5B in annual revenue with strong year-over-year growth of 10.70%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 53.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 3902.T's fundamental strength across five key dimensions:
Efficiency Score
Weak3902.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate3902.T shows balanced valuation metrics.
Growth Score
Moderate3902.T shows steady but slowing expansion.
Financial Health Score
Excellent3902.T maintains a strong and stable balance sheet.
Profitability Score
Weak3902.T struggles to sustain strong margins.
Key Financial Metrics
Is 3902.T Expensive or Cheap?
P/E Ratio
3902.T trades at 227.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 3902.T's PEG of 0.72 indicates potential undervaluation.
Price to Book
The market values Medical Data Vision Co., Ltd. at 20.68 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 374.56 times EBITDA. This signals the market has high growth expectations.
How Well Does 3902.T Make Money?
Net Profit Margin
For every $100 in sales, Medical Data Vision Co., Ltd. keeps $4.29 as profit after all expenses.
Operating Margin
Core operations generate 5.40 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.63 in profit for every $100 of shareholder equity.
ROA
Medical Data Vision Co., Ltd. generates $5.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medical Data Vision Co., Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Medical Data Vision Co., Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
3902.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
227.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.72
vs 25 benchmark
P/B Ratio
Price to book value ratio
20.68
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.75
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.22
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How 3902.T Stacks Against Its Sector Peers
| Metric | 3902.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 227.48 | 28.92 | Worse (Expensive) |
| ROE | 9.63% | 747.00% | Weak |
| Net Margin | 4.29% | -49468.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.40 | Strong (Low Leverage) |
| Current Ratio | 2.22 | 4.13 | Strong Liquidity |
| ROA | 5.86% | -19478.00% (disorted) | Weak |
3902.T outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medical Data Vision Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
49.01%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-58.23%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-15.35%
Industry Style: Defensive, Growth, Innovation
Declining